Results 221 to 230 of about 32,524 (285)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim We assessed the association between tirzepatide and the 10‐year predicted risk of developing cardiovascular disease (CVD) and type 2 diabetes (T2D) among three‐year SURMOUNT‐1 trial participants. Materials and Methods This post hoc analysis applied validated risk engines that predict 10‐year CVD (atherosclerotic cardiovascular disease ...
Emily R. Hankosky, Jeremie Lebrec, Clare J. Lee, Georgios K. Dimitriadis, Irina Jouravskaya, Adam Stefanski, W. Timothy Garvey   +6 more
wiley   +1 more source

Parameters of glycemic variability in continuous glucose monitoring as predictors of diabetes: a prospective evaluation in a non-diabetic general population. [PDF]

Adv Lab Med
Rodríguez García J, Camiña Darriba F, Ortolá Devesa JB, Rodríguez-Segade Villamarín S, Valle Rodríguez A.   +4 more
europepmc   +1 more source

Partial non‐adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross‐sectional study using blood plasma analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate medication adherence in patients with type 2 diabetes (T2D) using plasma drug measurements and assess the clinical impact of partial non‐adherence on glycemic control and complications. Materials and Methods This cross‐sectional study included 641 T2D outpatients attending routine follow‐up visits.
Vojtěch Škop, Ivana Laňková, Simona Antalová, Iva Míšková, Kateřina Malá‐Ládová, Josef Malý, Terezie Pelikánová, Jiří Hricko, Tomáš Čajka, Martin Haluzík   +9 more
wiley   +1 more source

Increased Risk of Alzheimer's Disease With Glycemic Variability: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Gonzales PNG, Ampil ER, Catindig-Dela Rosa JS, Villaraza SG, Joson MLC.   +4 more
europepmc   +1 more source

Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract This systematic review examines the current literature on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)‐associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders.
Brianna Sa, Anthony Maristany, Ashwin Subramaniam, Ryan Guillen, Brooke Buonocore, Audrey Smith, Sean E. Oldak, Vanessa Padilla   +7 more
wiley   +1 more source

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose‐dependent insulinotropic polypeptide, glucagon‐like peptide‐1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications—obstructive sleep apnea
Kathryn Giblin, Lee M. Kaplan, Virend K. Somers, Carel W. Le Roux, David J. Hunter, Qiwei Wu, Amy Lalonde, Nadia Ahmad, Mary Angelyn Bethel   +8 more
wiley   +1 more source

Glycemic variability and its association with short and long term clinical outcomes in critically ill patients with cerebral hemorrhage. [PDF]

Sci Rep
Wang D, He C, Zou S, Yu L, Han B, He L, Liu A, Hong Y, Li Q.   +8 more
europepmc   +1 more source

Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background There is little data on how semaglutide affects basal versus bolus insulin and dosing parameters in adults with type 1 diabetes on insulin pump therapy. Methods This is a post‐hoc analysis of a double‐blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Melissa‐Rosina Pasqua, Michael A. Tsoukas, Ahmad Haidar   +2 more
wiley   +1 more source

Low serum 1,5‐anhydroglucitol is associated with increased risk of all‐cause and cardiovascular mortality in type 2 diabetes: A real‐world cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Serum 1,5‐anhydroglucitol (1,5‐AG) indicates glycemic control over 1–2 weeks and is particularly useful for monitoring postprandial hyperglycemia. However, its predictive value for long‐term outcomes in type 2 diabetes has not been fully established.
Jiaying Ni, Lei Chen, Hang Su, Jinghao Cai, Chunfang Wang, Wei Lu, Yufei Wang, Jingyi Lu, Tian Xia, Jian Zhou   +9 more
wiley   +1 more source

U-shaped association between the glycemic variability and prognosis in hemorrhagic stroke patients: a retrospective cohort study from the MIMIC-IV database. [PDF]

Front Endocrinol (Lausanne)
Liu Y, Fu H, Wang Y, Sun J, Zhang R, Zhong Y, Yang T, Han Y, Xiang Y, Yuan B, Zhou R, Chen M, Wang H.   +12 more
europepmc   +1 more source